Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats unresectable or metastatic melanoma. Sold as Keytruda. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Pembrolizumab (sold as Keytruda), first approved Sep 4, 2014, with 109 new uses approved and 0 published complete response letters.
First approved: Sep 4, 2014
Applications: 1
New uses approved: 109
Complete response letters: 0
Medicare spending, 2025: $6.55B
Orphan exclusivity until: Jan 25, 2031
First approved in the EU: Jul 17, 2015
First approved in Japan: Sep 28, 2016
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 25 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
KeytrudaA drug with a new indication and a new dosage for the preoperative and postoperative adjuvant treatment for locally advanced head and neck cancer. · MSD K.K. · Feb 19, 2026
KeytrudaA drug with a new indication for the treatment of unresectable advanced or recurrent malignant pleural mesothelioma. · MSD K.K. · May 19, 2025
KeytrudaA drug with a new indication and a new dosage for the treatment of advanced or recurrent endometrial cancer. · MSD K.K. · Dec 27, 2024
KeytrudaA drug with a new indication and a new dosage for the treatment of locally advanced cervical cancer. · MSD K.K. · Nov 22, 2024
KeytrudaA drug with a new indication for the treatment of unresectable urothelial carcinoma. · MSD K.K. · Sep 24, 2024
KeytrudaA drug with a new indication and a new dosage for the preoperative and postoperative adjuvant treatment for non-small cell lung cancer. · MSD K.K. · Aug 28, 2024
KeytrudaA drug with a new indication and a new dosage for the treatment of unresectable advanced or recurrent gastric cancer. · MSD K.K. · May 17, 2024
KeytrudaA drug with a new indication and a new dosage for the treatment of unresectable biliary tract cancer. · MSD K.K. · May 17, 2024
Clinical Trials
1,363 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA